Analyst: This will be crucial to Novo’s haemophilia drug
The latest data from a phase III study with Novo Nordisk’s haemophilia drug N9-GP are highly positive, says analyst Søren Løntoft Hansen and points out one factor that will determine the success of the drug on an extremely conservative market.
by Stefan Singh Kailay
It is positive news for Novo, says analyst Søren Løntoft Hansen, Sydbank, about last week’s publication of data from a phase III study with company’s drug against haemophilia B, N9-GP.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
